Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 10-K Annual report
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1 12.31.2018
- 23.2 Exhibit 23.2 12.31.2018
- 23.3 Exhibit 23.3 12.31.2018
- 24.1 Exhibit 24.1 12.31.2018
- 31.1 Exhibit 31.1 12.31.2018
- 31.2 Exhibit 31.2 12.31.2018
- 32.1 Exhibit 32.1 12.31.2018
- 32.2 Exhibit 32.2 12.31.2018
- Download Excel data file
- View Excel data file
Related press release
Associated NHIQ transcripts
NHIQ similar filings
Filing view
External links
Exhibit 23.3
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-3 No. 333-223744) of NantHealth, Inc., and |
(2) | Registration Statement (Form S-8 Nos. 333-211886 and 333-225670) pertaining to the 2016 Equity Incentive Plan and Phantom Unit Plan of NantHealth, Inc. |
of our report dated March 29, 2019 with respect to the consolidated financial statements of NantOmics, LLC and subsidiaries, which comprise the consolidated balance sheet as of December 31, 2018, and the related consolidated statements of operations and comprehensive loss, changes in members’ equity, and cash flow for the year ended December 31, 2018, and the related notes to the consolidated financial statements.
/s/ Ernst & Young LLP | |
Los Angeles, California | |
March 29, 2019 | |